查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1878815

液體活體組織切片市場－全球產業規模、佔有率、趨勢、機會和預測，按產品、技術、工作流程、樣本、循環生物標記、應用、最終用戶、地區和競爭格局細分，2020-2030年預測

Liquid Biopsy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Offering, By Technology, By Workflow, By Sample, By Circulating Biomarkers, By Application, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球液體切片市場規模為49.3億美元，預計2030年將以12.50%的複合年成長率成長至99.9億美元。全球液體活體組織切片市場專注於檢測和分析體液（主要是血液）中存在的遺傳物質（例如循環腫瘤DNA和循環腫瘤細胞）的診斷測試。這種非侵入性方法有助於早期發現癌症、監測治療效果和識別基因突變，與傳統的組織活體組織切片相比具有許多優勢。

市場概覽
預測期 2026-2030
2024年市場規模 49.3億美元
2030年市場規模 99.9億美元
2025-2030年複合年成長率 12.5%
成長最快的細分市場 下一代定序（NGS）
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球液體切片市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 透過提供（測試服務、試劑盒、平台、其他耗材）
    • 依技術分類（聚合酶鍊式反應（PCR）、次世代定序（NGS）、其他）
    • 依工作流程（樣本製備、文庫製備、定序、資料分析與管理）
    • 依樣本類型（血液、尿液、唾液、其他）
    • 透過循環生物標記（循環腫瘤細胞 (CTC)、遊離核酸、外泌體和細胞外囊泡）
    • 依應用領域（腫瘤科、非腫​​瘤科）
    • 按最終用戶（臨床實驗室、學術和研究機構、製藥和生物技術公司）分類
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美液體切片市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲液體切片市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區液體切片市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲液體切片市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲液體切片市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新進展

第13章：全球液體切片市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific, Inc.
  • PerkinElmer Inc.
  • LungLife AI, Inc.
  • Illumina, Inc.
  • QIAGEN NV
  • NeoGenomics Laboratories, Inc.
  • Myriad Genetics, Inc.
  • Bio-Rad Laboratories, Inc.
  • Guardant Health Inc.
  • Natera, Inc.
  • Sysmex Corporation
  • Abcodia Ltd.
  • Dxcover Limited

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 12950

The Global Liquid Biopsy Market, valued at USD 4.93 Billion in 2024, is projected to experience a CAGR of 12.50% to reach USD 9.99 Billion by 2030. The global liquid biopsy market focuses on diagnostic tests that detect and analyze genetic material, such as circulating tumor DNA and circulating tumor cells, present in bodily fluids, primarily blood. This non-invasive approach facilitates early cancer detection, treatment monitoring, and identification of genetic mutations, offering advantages over traditional tissue

Market Overview
Forecast Period2026-2030
Market Size 2024USD 4.93 Billion
Market Size 2030USD 9.99 Billion
CAGR 2025-203012.5%
Fastest Growing SegmentNext Generation Sequencing (NGS)
Largest MarketNorth America

Key Market Drivers

The global liquid biopsy market's expansion is fundamentally propelled by the escalating worldwide cancer burden. The significant increase in cancer diagnoses necessitates accessible, less invasive diagnostic and monitoring tools. According to the World Health Organization and the International Agency for Research in Cancer, in their February 2024 news release "Global cancer burden growing, amidst mounting need for services", an estimated 20 million new cancer cases occurred worldwide in 2022. This prevalence drives demand for technologies enabling early detection, treatment guidance, and disease monitoring with minimal patient discomfort. Increasing regulatory and clinical validation supports market penetration.

Key Market Challenges

The prevailing concern regarding test accuracy and the absence of universally standardized procedures across various platforms presents a significant impediment to the growth of the global liquid biopsy market. The lack of consistent protocols for assay development, validation, and reporting contributes to variable test performance and potentially inaccurate outcomes. This directly undermines the confidence of healthcare providers in integrating liquid biopsy into routine clinical practice, slowing its broader adoption.

For example, according to a 2024 International Association for the Study of Lung Cancer Global Survey, 26% of surveyed institutions were unaware of any biomarker testing guidelines, while only 54% utilized the comprehensive CAP-IASLC-AMP guidelines. Such discrepancies in guideline awareness and implementation highlight the fragmented landscape of liquid biopsy utilization. This variability complicates comparative analysis across different platforms and laboratories, making it difficult for clinicians to fully trust and rely on the results for critical treatment decisions. Consequently, the market experiences slower expansion as stakeholders exercise caution due to these unresolved issues in standardization and perceived reliability.

Key Market Trends

Multi-analyte and multi-cancer screening development is significantly driving the global liquid biopsy market by enabling the simultaneous detection of various cancer types from a single blood sample. This trend promotes broader, earlier cancer identification, enhancing preventative care and treatment outcomes. In March 2024, the National Institutes of Health launched its Cancer Screening Research Network to evaluate multi-cancer early detection tests, initiating a Vanguard Study enrolling up to 24,000 participants. This highlights national commitment to validating advanced diagnostics. Further demonstrating progress, Exai Bio presented data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, showing its RNA- and AI-based platform achieved 87% overall stage I sensitivity across eight cancer types at 95% specificity in a 3,300 subject study.

Key Market Players

  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific, Inc.
  • PerkinElmer Inc.
  • LungLife AI, Inc.
  • Illumina, Inc.
  • QIAGEN NV
  • NeoGenomics Laboratories, Inc.
  • Myriad Genetics, Inc.
  • Bio-Rad Laboratories, Inc.
  • Guardant Health Inc.
  • Natera, Inc.
  • Sysmex Corporation
  • Abcodia Ltd.
  • Dxcover Limited

Report Scope:

In this report, the Global Liquid Biopsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Liquid Biopsy Market, By Offering:

  • Testing Services
  • Kits
  • Platform
  • Other Consumables

Liquid Biopsy Market, By Technology:

  • Polymerase Chain Reaction (PCR)
  • Next Generation Sequencing (NGS)
  • Others

Liquid Biopsy Market, By Workflow:

  • Sample Preparation
  • Library Preparation
  • Sequencing
  • Data Analysis & Management

Liquid Biopsy Market, By Sample:

  • Blood
  • Urine
  • Saliva
  • Others

Liquid Biopsy Market, By Circulating Biomarkers:

  • Circulating Tumor Cells (CTCs)
  • Cell-free Nucleic Acids
  • Exosomes & Extracellular Vesicles

Liquid Biopsy Market, By Application:

  • Oncological
  • Non-oncological

Liquid Biopsy Market, By End User:

  • Clinical Laboratories
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies

Liquid Biopsy Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Liquid Biopsy Market.

Available Customizations:

Global Liquid Biopsy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Liquid Biopsy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Offering (Testing Services, Kits, Platform, Other Consumables)
    • 5.2.2. By Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Others)
    • 5.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
    • 5.2.4. By Sample (Blood, Urine, Saliva, Others)
    • 5.2.5. By Circulating Biomarkers (Circulating Tumor Cells (CTCs), Cell-free Nucleic Acids, Exosomes & Extracellular Vesicles)
    • 5.2.6. By Application (Oncological, Non-oncological)
    • 5.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
    • 5.2.8. By Region
    • 5.2.9. By Company (2024)
  • 5.3. Market Map

6. North America Liquid Biopsy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Offering
    • 6.2.2. By Technology
    • 6.2.3. By Workflow
    • 6.2.4. By Sample
    • 6.2.5. By Circulating Biomarkers
    • 6.2.6. By Application
    • 6.2.7. By End User
    • 6.2.8. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Liquid Biopsy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Offering
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Workflow
        • 6.3.1.2.4. By Sample
        • 6.3.1.2.5. By Circulating Biomarkers
        • 6.3.1.2.6. By Application
        • 6.3.1.2.7. By End User
    • 6.3.2. Canada Liquid Biopsy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Offering
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Workflow
        • 6.3.2.2.4. By Sample
        • 6.3.2.2.5. By Circulating Biomarkers
        • 6.3.2.2.6. By Application
        • 6.3.2.2.7. By End User
    • 6.3.3. Mexico Liquid Biopsy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Offering
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Workflow
        • 6.3.3.2.4. By Sample
        • 6.3.3.2.5. By Circulating Biomarkers
        • 6.3.3.2.6. By Application
        • 6.3.3.2.7. By End User

7. Europe Liquid Biopsy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Offering
    • 7.2.2. By Technology
    • 7.2.3. By Workflow
    • 7.2.4. By Sample
    • 7.2.5. By Circulating Biomarkers
    • 7.2.6. By Application
    • 7.2.7. By End User
    • 7.2.8. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Liquid Biopsy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Offering
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Workflow
        • 7.3.1.2.4. By Sample
        • 7.3.1.2.5. By Circulating Biomarkers
        • 7.3.1.2.6. By Application
        • 7.3.1.2.7. By End User
    • 7.3.2. France Liquid Biopsy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Offering
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Workflow
        • 7.3.2.2.4. By Sample
        • 7.3.2.2.5. By Circulating Biomarkers
        • 7.3.2.2.6. By Application
        • 7.3.2.2.7. By End User
    • 7.3.3. United Kingdom Liquid Biopsy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Offering
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Workflow
        • 7.3.3.2.4. By Sample
        • 7.3.3.2.5. By Circulating Biomarkers
        • 7.3.3.2.6. By Application
        • 7.3.3.2.7. By End User
    • 7.3.4. Italy Liquid Biopsy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Offering
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Workflow
        • 7.3.4.2.4. By Sample
        • 7.3.4.2.5. By Circulating Biomarkers
        • 7.3.4.2.6. By Application
        • 7.3.4.2.7. By End User
    • 7.3.5. Spain Liquid Biopsy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Offering
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Workflow
        • 7.3.5.2.4. By Sample
        • 7.3.5.2.5. By Circulating Biomarkers
        • 7.3.5.2.6. By Application
        • 7.3.5.2.7. By End User

8. Asia Pacific Liquid Biopsy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Offering
    • 8.2.2. By Technology
    • 8.2.3. By Workflow
    • 8.2.4. By Sample
    • 8.2.5. By Circulating Biomarkers
    • 8.2.6. By Application
    • 8.2.7. By End User
    • 8.2.8. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Liquid Biopsy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Offering
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Workflow
        • 8.3.1.2.4. By Sample
        • 8.3.1.2.5. By Circulating Biomarkers
        • 8.3.1.2.6. By Application
        • 8.3.1.2.7. By End User
    • 8.3.2. India Liquid Biopsy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Offering
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Workflow
        • 8.3.2.2.4. By Sample
        • 8.3.2.2.5. By Circulating Biomarkers
        • 8.3.2.2.6. By Application
        • 8.3.2.2.7. By End User
    • 8.3.3. Japan Liquid Biopsy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Offering
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Workflow
        • 8.3.3.2.4. By Sample
        • 8.3.3.2.5. By Circulating Biomarkers
        • 8.3.3.2.6. By Application
        • 8.3.3.2.7. By End User
    • 8.3.4. South Korea Liquid Biopsy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Offering
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Workflow
        • 8.3.4.2.4. By Sample
        • 8.3.4.2.5. By Circulating Biomarkers
        • 8.3.4.2.6. By Application
        • 8.3.4.2.7. By End User
    • 8.3.5. Australia Liquid Biopsy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Offering
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Workflow
        • 8.3.5.2.4. By Sample
        • 8.3.5.2.5. By Circulating Biomarkers
        • 8.3.5.2.6. By Application
        • 8.3.5.2.7. By End User

9. Middle East & Africa Liquid Biopsy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Offering
    • 9.2.2. By Technology
    • 9.2.3. By Workflow
    • 9.2.4. By Sample
    • 9.2.5. By Circulating Biomarkers
    • 9.2.6. By Application
    • 9.2.7. By End User
    • 9.2.8. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Liquid Biopsy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Offering
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Workflow
        • 9.3.1.2.4. By Sample
        • 9.3.1.2.5. By Circulating Biomarkers
        • 9.3.1.2.6. By Application
        • 9.3.1.2.7. By End User
    • 9.3.2. UAE Liquid Biopsy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Offering
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Workflow
        • 9.3.2.2.4. By Sample
        • 9.3.2.2.5. By Circulating Biomarkers
        • 9.3.2.2.6. By Application
        • 9.3.2.2.7. By End User
    • 9.3.3. South Africa Liquid Biopsy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Offering
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Workflow
        • 9.3.3.2.4. By Sample
        • 9.3.3.2.5. By Circulating Biomarkers
        • 9.3.3.2.6. By Application
        • 9.3.3.2.7. By End User

10. South America Liquid Biopsy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Offering
    • 10.2.2. By Technology
    • 10.2.3. By Workflow
    • 10.2.4. By Sample
    • 10.2.5. By Circulating Biomarkers
    • 10.2.6. By Application
    • 10.2.7. By End User
    • 10.2.8. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Liquid Biopsy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Offering
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Workflow
        • 10.3.1.2.4. By Sample
        • 10.3.1.2.5. By Circulating Biomarkers
        • 10.3.1.2.6. By Application
        • 10.3.1.2.7. By End User
    • 10.3.2. Colombia Liquid Biopsy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Offering
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Workflow
        • 10.3.2.2.4. By Sample
        • 10.3.2.2.5. By Circulating Biomarkers
        • 10.3.2.2.6. By Application
        • 10.3.2.2.7. By End User
    • 10.3.3. Argentina Liquid Biopsy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Offering
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Workflow
        • 10.3.3.2.4. By Sample
        • 10.3.3.2.5. By Circulating Biomarkers
        • 10.3.3.2.6. By Application
        • 10.3.3.2.7. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Liquid Biopsy Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. F. Hoffmann-La Roche Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Thermo Fisher Scientific, Inc.
  • 15.3. PerkinElmer Inc.
  • 15.4. LungLife AI, Inc.
  • 15.5. Illumina, Inc.
  • 15.6. QIAGEN NV
  • 15.7. NeoGenomics Laboratories, Inc.
  • 15.8. Myriad Genetics, Inc.
  • 15.9. Bio-Rad Laboratories, Inc.
  • 15.10. Guardant Health Inc.
  • 15.11. Natera, Inc.
  • 15.12. Sysmex Corporation
  • 15.13. Abcodia Ltd.
  • 15.14. Dxcover Limited

16. Strategic Recommendations

17. About Us & Disclaimer